Literature DB >> 30511889

Long-term Outcome for Open and Endoscopically Resected Sinonasal Tumors.

Jan Hagemann1,2, Jana Roesner2, Soenke Helling2, Christian Jacobi3, Johannes Doescher4, Matthias Engelbarts1, Julian Kuenzel1, Philipp Krauss5, Sven Becker1, Christian Stephan Betz6.   

Abstract

OBJECTIVE: Endoscopic resection of sinonasal cancer has become an alternative to open craniofacial surgery and leads to safe and satisfying results in emerging numbers. Randomized study data comparing outcomes between approaches are missing. Hence, it remains unclear which subgroups of patients might profit most from each technique. We aimed to identify such patient and tumor characteristics and gather information for future prospective study design. STUDY
DESIGN: Case series with chart review.
SETTING: Tertiary academic center. SUBJECTS AND METHODS: This study is based on a retrospective chart review of 225 patients undergoing open craniofacial or endoscopic resection for sinonasal malignancy between 1993 and 2015 at Munich University Hospital. Statistical analyses include t test, chi-square, Kaplan-Meier charts, and univariate and multivariate analyses.
RESULTS: The sample size was similar between the endoscopic and open surgery groups. Tumors were significantly larger in patients who underwent open craniofacial resection. The risk of notable bleeding ( P = .041) was lower and hospital stay shorter ( P = .001) for endoscopic interventions of all tumor stages. Rates of overall ( P = .024) and disease-specific ( P = .036) survival were significantly improved for endoscopic cases; improved recurrence-free survival rates did not achieve statistical significance ( P = .357). For cases matched for tumor size, this improvement was confirmed for T3 tumors ( P = .038). Regional and distant metastatic tumor spread generally worsened survival in both surgical subgroups. Multivariate Cox regression analysis revealed independent prognosticators for overall survival.
CONCLUSION: Endoscopic tumor resection remains a suitable option for distinct indications and showed improved outcome in intermediate-stage tumors in our collective. Further randomized studies acknowledging the here-identified factors are needed to improve future therapy guidelines and patient care.

Entities:  

Keywords:  CSF leak; endoscopic sinus surgery; endoscopic skull base surgery; head and neck cancer; sinonasal cancer

Mesh:

Year:  2018        PMID: 30511889     DOI: 10.1177/0194599818815881

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  4 in total

1.  Cost-Effectiveness of Routine Type and Screens in Select Endonasal Skull Base Surgeries.

Authors:  Aviv Spillinger; Meredith Allen; Patrick Karabon; Houmehr Hojjat; Kerolos Shenouda; Inaya Hajj Hussein; Jeffrey T Jacob; Peter F Svider; Adam J Folbe
Journal:  J Neurol Surg B Skull Base       Date:  2021-05-31

2.  Comparative Outcomes by Surgical Approach in Patients with Malignant Sinonasal Disease.

Authors:  Nicholas R Lenze; Carolyn Quinsey; Deanna Sasaki-Adams; Matthew G Ewend; Brian D Thorp; Charles S Ebert; Adam M Zanation
Journal:  J Neurol Surg B Skull Base       Date:  2021-05-29

Review 3.  The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours.

Authors:  Fernando López; Jatin P Shah; Jonathan J Beitler; Carl H Snyderman; Valerie Lund; Cesare Piazza; Antti A Mäkitie; Orlando Guntinas-Lichius; Juan P Rodrigo; Luiz P Kowalski; Miquel Quer; Ashok Shaha; Akihiro Homma; Alvaro Sanabria; Renata Ferrarotto; Anne W M Lee; Victor H F Lee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Adv Ther       Date:  2022-03-30       Impact factor: 4.070

Review 4.  Interdisciplinary challenges and aims of flap or graft reconstruction surgery of sinonasal cancers: What radiologists and radiation oncologists need to know.

Authors:  Florent Carsuzaa; Benjamin Verillaud; Pierre-Yves Marcy; Philippe Herman; Xavier Dufour; Valentin Favier; Juliette Thariat
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.